NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Achillion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACHN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACHN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Achillion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ACHN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Achillion Pharmaceuticals. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
10/18/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$5.00 ➝ $6.30Medium
5/3/2019BarclaysDowngradeEqual Weight ➝ Underweight$5.00 ➝ $2.50Low
3/7/2019William BlairReiterated RatingOutperformMedium
5/21/2018BarclaysUpgradeUnderweight ➝ Equal Weight$5.00High
2/8/2018B. RileyInitiated CoverageNeutral ➝ Neutral$3.50Medium
12/11/2017SVB LeerinkReiterated RatingBuy$5.00Medium
9/17/2017Chardan CapitalReiterated RatingNeutralHigh
9/12/2017LADENBURG THALM/SH SHLower Price TargetBuy ➝ Buy$9.00 ➝ $6.50High
9/12/2017Robert W. BairdReiterated RatingNeutral$5.00 ➝ $4.00High
8/10/2017Robert W. BairdDowngradeOutperform ➝ Neutral$5.00High
8/9/2017Maxim GroupSet Price TargetBuy$5.00 ➝ $7.00High
8/9/2017Chardan CapitalLower Price TargetNeutral$5.00 ➝ $4.00High
5/18/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00High
4/26/2017Jefferies Financial GroupReiterated RatingHoldLow
4/25/2017Maxim GroupLower Price TargetBuy$8.00 ➝ $5.00High
4/24/2017Robert W. BairdBoost Price TargetOutperform$5.00 ➝ $10.00High
2/2/2017LADENBURG THALM/SH SHInitiated CoverageBuy$10.00N/A
11/6/2016Robert W. BairdReiterated RatingOutperform$10.00N/A
11/4/2016Chardan CapitalUpgradeSell ➝ Neutral$5.00N/A
11/3/2016WedbushReiterated RatingOutperform$13.00N/A
11/3/2016SVB LeerinkReiterated RatingMarket PerformN/A
9/26/2016Jefferies Financial GroupReiterated RatingHoldN/A
9/23/2016Chardan CapitalBoost Price TargetSell$4.00 ➝ $5.00N/A
9/22/2016WedbushInitiated CoverageOutperformN/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Achillion Pharmaceuticals logo
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $6.76
Low: $6.76
High: $6.76

52 Week Range

Now: N/A

Volume

N/A

Average Volume

8,439,141 shs

Market Capitalization

$946.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Achillion Pharmaceuticals?

The following Wall Street analysts have issued research reports on Achillion Pharmaceuticals in the last year:
View the latest analyst ratings for ACHN.

What is the current price target for Achillion Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Achillion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Achillion Pharmaceuticals in the next year.
View the latest price targets for ACHN.

What is the current consensus analyst rating for Achillion Pharmaceuticals?

Achillion Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ACHN.

What other companies compete with Achillion Pharmaceuticals?

How do I contact Achillion Pharmaceuticals' investor relations team?

Achillion Pharmaceuticals' physical mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company's listed phone number is 203-624-7000. The official website for Achillion Pharmaceuticals is www.achillion.com.